Portfolio Companies Archive

CyDex Announces Capitsol Technology Used in Injection Formulation of Veterinary Anti-Emetic Cerenia® (Maropitant) Recently Approved for Marketing in Europe -- April 10, 2007

Xoft, Inc., Announces Additional Funding for Breakthrough Electronic Brachytherapy Technology -- April 4, 2007

Calypso® Medical Technologies, Inc., $42.2M Private Equity Financing Provides Expansion Capital -- January 5, 2007

CyDex Announces Capitsol Technology Used In Recently Launched Injection Formulation of Antipsychotic Medication Abilify® (aripiprazole) -- December 14, 2006

IDev Technologies, Inc closes $19 Million Financing -- November 30, 2006

Pharmion Acquires Cabrellis Pharmaceuticals -- November 15, 2006

Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union -- November 15, 2006

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications -- October 3, 2006

Cabrellis Pharmaceuticals announces corporate launch and founding management team. -- May 17, 2006

MacroGenics Raises $45 Million in Series C Financing - Company to Advance Monclonal Antibody Clinical Programs -- May 15, 2006

Biogen Idec to Expand Oncology Pipeline with Acquisition of Conforma Therapeutics -- May 3, 2006

Accumetrics Raises $8.25 Million in Series C Financing -- January 20, 2006

CyDex, Inc. Names Jose L. Rodriguez Vice President of Business Development -- January 5, 2006

CyDex, Inc. Names Jose L. Rodriguez Vice President of Business Development -- January 5, 2006

FDA Clears Xoft's Axxent™ Electronic Brachytherapy Sysystem for Treatment of Breast Cancer -- January 4, 2006

Kereos Appoints Allen Nickols, Ph.D. as Vice President Of Biology -- December 13, 2005

Kereos' Collaborators Present On Targeted Therapies For -- November 15, 2005

90 Percent of Radiation Oncology Professionals Surveyed Believed Electronic Brachytherapy is an Exciting New Cancer Treatment Tool -- November 4, 2005

Real-Time Target Localization in Radiation Therapy Explored -- October 16, 2005

Kereos Increases Series B Financing Total to $20 Million -- October 14, 2005

Xoft Signs An Agreement For Distribution of Varian Medical Systems' Brachyvision Treatment Planning Software -- October 13, 2005

Kereos Secures $19.5 million in Series B Financing -- September 20, 2005

CyDex Reports First Approval of Captisol-Enabled® Drug in Japan -- August 10, 2005

Electronic Brachytherapy Accurately Delivers Non-Radioactive Radiation Therapy Directly to Tumor Sites -- July 22, 2005

Leading Cancer Centers Commence Clinical Study for Prostate Cancer Patients Receiving External Beam Radiation Therapy -- July 19, 2005

Cellular Genomics Selects Drug Development Candidate in Proprietary Angiogenesis Inhibitor Program; Changes Corporate Name to CGI Pharmaceuticals -- July 13, 2005

Conforma Therapeutics Corporation Acquires Late Stage Anti-Cancer Compound from Sumitomo Pharmaceuticals Co., Ltd. -- June 29, 2005

St. Jude Medical Completes Acquisition of Velocimed -- April 6, 2005

Xcyte Therapies, Inc. Announces Full-Year and Fourth Quarter 2004 Financial Results -- March 31, 2005

Xcyte Therapies, Inc. Updates Clinical Development Plans -- March 23, 2005

Xcyte Therapies, Inc. Appoints Christopher Henney as Chairman of the Board of Directors -- March 22, 2005

Xcyte Therapies, Inc. to Present at the Wells Fargo Securities 2005 Healthcare Conference -- February 22, 2005

Xcyte Therapies, Inc. Announces Publication of Paper Describing Mechanism of Action of Xcellerated T Cells in Chronic Lymphocytic Leukemia -- February 15, 2005

St. Jude Medical Announces Agreement to Acquire Velocimed -- February 15, 2005

Xcyte Therapies, Inc. Presents Results of Two Clinical Trials of Xcellerated T Cells at Tandem BMT Meetings -- February 14, 2005

Xcyte Therapies, Inc. Announces Withdrawal of Protocol for Phase II/III Clinical Trial Chronic Lymphocytic Leukemia and Potential Delay in Trial Initiation -- February 2, 2005

Xcyte Therapies, Inc. to Present at the Piper Jaffray Health Care Conference -- January 19, 2005

Xcyte Therapies, Inc. Announces Quarterly Divident for 6% Convertible Exchangeable Preferred Stock -- January 10, 2005

Velocimed Announces CE Mark for its Premere PFO Closure System -- January 6, 2005

Xcyte Therapies, Inc. Presents Results of Two Clinical Trials of Xcellerated T Cells in Multiple Myeloma at American Society of Hematology Meeting -- December 6, 2004

Xcyte Therapies, Inc. Presents Results of Phase I/II Clinical Trial of Xcellerated T Cells in Chronic Lymphocytic Leukemia at American Society of Hematology Meeting; Discusses Plans for Phase II/III Trial -- December 6, 2004

Kereos and Washington University to develop therapeutics for unstable plaque under new $7.3 Million grant -- November 18, 2004

Xcyte Therapies, Inc. to Present at the Granite Financial Group Healthcare Investors Conference -- November 17, 2004

Xcyte Therapies, Inc. Announces Third Quarter 2004 Financial Results -- November 11, 2004

CyDex, Inc. Presents Promising Study Results in Developing New Pharmaceutical Products -- November 10, 2004

Xcyte Therapies, Inc. Announces Exercise of Over-Allotment Option and Closing of Public Offering of 6% Convertible Exchangeable Preferred Stock -- November 3, 2004

Xcyte Therapies, Inc. Announces Pricing for Public Offering of 6% Convertible Exchangeable Preferred Stock -- October 29, 2004

CyDex, Inc. Earns Rapid Growth Ranking in Deloitte Technology Fast 500 -- October 20, 2004

Xcyte Therapies, Inc. Files Registration Statement for Public Offering of Convertible Exchangeable Preferred Stock -- October 7, 2004

Robert L. De Jager, M.D., F.A.C.P. Joins Conforma Therapeutics as Vice President, Clinical Research & Development and Chief Medical Officer -- October 6, 2004

Calypso Medical and Philips Announce Strategic Collaboration to Improve Precision of Cancer Treatment -- October 5, 2004

Cellular Genomics Appoints Dr. Udo Klein Senior Vice President of Drug Development -- October 4, 2004

Calypso Medical Announces a Strategic Collaboration Agreement with IMPAC Medical Systems at the ASTRO 46th Annual Meeting -- October 3, 2004

Clinical Study Preliminary Results Presented on the Calypso 4D Localization System at the ASTRO 46th Annual Meeting -- September 29, 2004

Velocimed® Announces Closing of Series D Financing and Significant Milestones Achieved for the Proxis®, Premere™ and Venture™ Products -- September 21, 2004

Kereos and Dow Sign Licensing Agreement for Novel Targeted Imaging Agents -- September 20, 2004

Xcyte Therapies, Inc. to Present at the Roth Capital Partners New York Conference -- September 8, 2004

Xcyte Therapies, Inc. Elects Daniel K. Spiegelman as Director -- September 8, 2004

CyDex, Inc. Raises $17 Million in Venture Capital to Advance Development of Drug Candidates -- August 17, 2004

Xcyte Therapies, Inc. Announces Second Quarter 2004 Financial Results -- August 12, 2004

Conforma Therapeutics Initiates Two Phase I Studies of HSP90 Inhibitor CNF1010 in Patients with Solid Tumors and Chronic Myelogenous Leukemia -- August 2, 2004

XCYTE THERAPIES, INC., APPOINTS LAWRENCE A. ROMEL AS VICE PRESIDENT OF CLINICAL OPERATIONS AND PROJECT MANAGEMENT -- July 29, 2004

Kereos Named Among Top 15 Biotech Companies of 2004 By FierceBiotech -- July 28, 2004

TissueLink President And CEO Jackie Eastwood Named The Ernst & Young New England Entrepreneur Of The Year® -- July 7, 2004

CYDEX, INC. LICENSES CAPTISOL ® TO TARGEGEN, INC. FOR CARDIOVASCULAR DRUG CANDIDATE AND FUTURE PIPELINE -- June 30, 2004

William J. Boyle, Ph.D., Joins Auxeris Therapeutics as Chief Scientific Officer -- June 22, 2004

HOVIONE AND CYDEX ANNOUNCE DRUG DEVELOPMENT ALLIANCE FOR SIX POTENTIAL NEW PRODUCTS -- June 14, 2004

Cellular Genomics Completes Series C Financing Raising $34.9 Million -- June 14, 2004

CYDEX, INC. ADDS DR. JOSEPH FIX TO MANAGEMENT TEAM -- June 11, 2004

Xcyte Therapies, Inc., Presents Results of Clinical Trials in Chronic Lymphocytic Leukemia, Multiple Myeloma, and Prostate Cancer -- June 7, 2004

Kereos Awarded Missouri Governor's Technology Award For New Approach to Combating Serious Diseases -- May 21, 2004

Xcyte Therapies, Inc. Announces First Quarter 2004 Financial Results -- May 13, 2004

Xcyte Therapies, Inc. Begins Construction of New Facility to Manufacture Xcellerated T Cells -- April 29, 2004

Kereos Appoints Michael Loberg, Nitromed President and CEO, to Board of Directors -- April 28, 2004

CyDex, Inc. Announces Preclinical Study Showing Potential of New Asthma Formulation Using Captisol® Solution -- April 26, 2004

Conforma Therapeutics Appoints Former Lilly Executive, Christopher LeMasters, as Vice President, Corporate Development -- April 19, 2004

XCYTE Therapies, Inc., Initiates Phase II Clinical Trail of Xcellerated T Cells in Patients with Relapsed Multiple Myeloma -- April 15, 2004

Xcyte Therapies, Inc. Announces Pricing of Initial Public Offering -- March 16, 2004

CyYDex, Inc. Announces Agreement with Array Biopharma Inc. -- March 9, 2004

CyDex Inc. Announces Agreement With Gilead Sciences, Inc. - Provides Gilead Use of Captisol for Early Clinical Study -- March 4, 2004

Bristol-Myers Squibb Medical Imaging and Kereos Enter Into Agreements to Develop Novel Molecular Imaging Agents -- March 2, 2004

Robert L. Kirkman, MD Appointed Chief Business Officer and Vice President of Xcyte Therapies -- January 22, 2004

Auxeris Therapeutics Acquires Oral Bone Forming Drug Candidate to Treat Osteoporosis -- January 14, 2004

TissueLink Medical Announces the Formation of its Orthopaedic Physician Advisory Board -- October 8, 2003

Nature Publication by Conforma Therapeutics Scientists Identifies Molecular Mechanism Underlying Tumor Selectivity of HSP90 Inhibitors -- September 24, 2003

CONFORMA THERAPEUTICS CORPORATION CLOSES $30 MILLION FINANCING -- September 18, 2003

Xcyte Therapies, Inc. Initiates Phase I/II Clinical Trial of Xcellerated T Cells in Chronic Lymphocytic Leukemia -- August 28, 2003

Velocimed™ Announces Start of U.S. IDE Clinical Trial, International Distribution Agreement with ev3 and Closing of Series C Financing -- July 2, 2003

CyDex, Inc. Announces Agreement Licensing Captisol® To Taisho Pharmaecutical Co., Ltd . -- May 29, 2003

CyDex, Inc. Names John M. Siebert, Ph.D. President and Chief Executive Officer. -- May 22, 2003

CyDex, Inc. Announces Agreement Licensing Captisol® To Teva Pharmaceutical Industries Ltd. -- April 30, 2003

Philips, Dow and Kereos Named as Collaborators in National Cancer Institute Contract -- April 24, 2003

CyDex, Inc. Announces Agreement With MERCK - Provides MERCK Ability To Use CAPTISOL® For Early Development -- March 5, 2003

Kereos, Inc. Names Robert A. Beardsley, Ph.D., CEO -- January 15, 2003

RiverVest Venture Partners and Baird Venture Partners Complete $10 Million Financing in Centerre Healthcare Corporation -- December 18, 2002

Auxeris Therapeutics Closes on Funding from RiverVest Venture Partners and Domain Associates -- October 23, 2002

Philips and KEREOS announce alliance on research and development for molecular imaging and diagnostics -- September 4, 2002

CYDEX, INC. ANNOUNCES SECOND U.S. APPROVAL OF A CAPTISOL-ENABLED™ PRESCRIPTION DRUG -- July 10, 2002

CYDEX, INC. ANNOUNCES FIRST U.S. APPROVAL OF A CAPTISOL-ENABLED™ MEDICATION -- June 10, 2002

TissueLink Medical Announces $14.5 Million Financing, Two New Board Members and New FDA Clearance -- April 5, 2002

CyDex, Inc. Licenses Captisol Drug Delivery System to OSI Pharmaceuticals, Inc. -- November 28, 2001

CyDex, Inc. Licenses Captisol to Suntory LTD. - Second Alliance with a Pharma Company in Japan -- November 14, 2001

NexRay Raises $21 Million in Private Financing Round -- October 23, 2001

Life Science Lab: CyDex provides case study in turning bioscience technology into revenues. -- September 28, 2001

TissueLink Medical Receives ISO 9001 Certification, Establishes TissueLink Europe S.r.l. -- April 17, 2001

TissueLink™ Medical Receives FDA 510(k) Clearance for the TissueLink Monopolar Floating Ball™ Device -- November 21, 2000

TissueLink Medical Secures $19.65 Million in Series B Financing -- October 20, 2000

CyDex, Inc., A Kansas City-based specialty pharmaceutical company announces completion of $12 million equity private placement. -- October 16, 2000